Business
Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results
Company to host conference call and webcast today at 5:00pm EDT HOUSTON, May 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"Company to host conference call and webcast today at 5:00pm EDT\n\n\n HOUSTON, May 11, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.\n\n \n \n \n \n \n \n\n \n\"While we are eager to initiate our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia (AML), we anticipate that the initiation of our trial will be delayed by the impacts the COVID-19 pandemic has had on our clinical trial partners and throughout our supply chain. As a result of the uncertainty, we believe it is prudent to withdraw our prior guidance on the timing of this trial until the outlook clarifies,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"Despite these pandemic-related effects, we remain optimistic that when the study opens, there will be significant patient interest. We are moving expediently in the interim to secure clinical trial sites and are monitoring the situation closely to prioritize the health and wellness of our employees and the patients we serve.\"\nContinued Mr. Hoang: \"We continue to be encouraged by the potential of our MultiTAA-specific T cell therapy to change the treatment paradigm for patients with both liquid and solid tumors. Recently, we received Orphan Drug designation from the U.S. FDA for MT-401, our MultiTAA-specific T cell product candidate to treat patients with AML post-stem cell transplant, our lead indication. Additionally, we are looking forward to soon reporting an update from an ongoing academic-sponsored trial in pancreatic adenocarcinoma, which will be presented during the upcoming ASCO annual meeting.\" \nPROGRAM UPDATES\nMulti-Antigen Targeted (MultiTAA) T Cell Therapies\nPhase 2 AML Trial Update Due to the COVID-19 pandemic, Marker expects to be delayed in initiating its planned Phase 2 trial in post-transplant AML patients per previously communicated timelines. Under an amended trial protocol announced in February 2020, the U.S. FDA cleared the Company to initiate the trial, beginning with a safety lead-in. Marker has pause...